Bristol Myers schizophrenia therapy safe in late-stage trial Markets April 6, 2024 [ad_1] hapabapa/iStock Editorial through Getty Pictures Bristol Myers Squibb (NYSE:BMY) introduced Saturday that its experimental schizophrenia remedy KarXT, acquired as…
J&J, Alkermes, AbbVie, others set to benefit from expanding schizophrenia drug market Finances October 22, 2022 [ad_1] Olivier Le Moal/iStock through Getty Photos A rise within the affected person inhabitants mixed with new therapies in growth…
